Barclays
GEVA

Barclays’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Barclays’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,907
Closed -$1.93M – 7446
2015
Q1 		$1.93M Buy
19,907
+17,771
+832% +$1.88M ﹤0.01% 2354
2014
Q4 		$196K Sell
2,136
-2,584
-55% -$204K ﹤0.01% 4653
2014
Q3 		$321K Sell
4,720
-5,384
-53% -$386K ﹤0.01% 4346
2014
Q2 		$1.05M Buy
10,104
+3,955
+64% +$336K ﹤0.01% 3281
2014
Q1 		$504K Sell
6,149
-1,866
-23% -$173K ﹤0.01% 3951
2013
Q4 		$514K Sell
8,015
-1,782
-18% -$106K ﹤0.01% 4068
2013
Q3 		$617K Buy
9,797
+7,522
+331% +$370K ﹤0.01% 3883
2013
Q2 		$95K Buy
+2,275
New +$104K ﹤0.01% 5837

Barclays's GEVA Position: Q2 2015 in Review

Barclays sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 19,907 shares — an estimated $1.93M sold.

Barclays first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.93M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Barclays reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Barclays sold 19,907 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.93M.
  • Barclays first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Barclays's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.93M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Barclays's 13F filing for Q2 2015, filed 14 Aug 2015.